Dallas, Texas 12/25/2013 (FINANCIALSTRENDS) – Thomson Reuters/Verus’ equity researchers downgraded Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) from a “hold” to a “sell” rating on Tuesday. Recently, numerous other equities-research analysts have weighed on the Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) stock. On 6 Friday, Merrill Lynch analysts assigned an “underperform” rating on the company stock. Bank of America Corp analysts initiated coverage on Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) shares on Friday, 6 December and have assigned an “underperform” rating on the stock with a PT of $1.50.
Gabelli analysts reiterated their “buy” rating on Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) shares on Friday, 11 October. Four research-analysts have assigned a “sell” rating on the Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) stock, and 2have have assigned a “buy” rating. Currently, the average rating on the Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) stock is a “Hold” and the average PT is $2.17.
Tuesday’s trading
In the trading session on Tuesday there was a drop of 1.05% in Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX). The shares opened at $1.91 climbed to an intraday high of $1.94 and closed at $1.89. Close to 0.497M shares were traded on Tuesday and the average volume of 1.35M shares got traded over a period of 30 days. The 52-week low of Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) shares is $1.70 while the 52-week high stands at $3.18. The company has a market capitalization of $970.55 million.
About the company
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) is a bio-pharma company that is focused on discovering and developing breakthrough treatments for different human diseases. The company uses its gene-knockout technologies & an integrated platform of its medical technologies to study physiological & behavioral functions of approximately 5,000 genes in mice & assessed utility of proteins that are encoded by the corresponding human- genes as the drug targets. It has 5 drug programs in different stages of clinical-development and advanced small-molecule compounds from numerous additional drug programs in various stages of pre-clinical development &research.